Related Experiment Video

Updated: Jun 17, 2026

Isolation of Leukocytes from Human Breast Milk for Use in an Antibody-dependent Cellular Phagocytosis Assay of HIV Targets
08:12

Isolation of Leukocytes from Human Breast Milk for Use in an Antibody-dependent Cellular Phagocytosis Assay of HIV Targets

Published on: September 6, 2019

Targeting Trojan Horse leukocytes for HIV prevention

Deborah J Anderson1, Joseph A Politch, Adam M Nadolski

  • 1Department of Obstetrics and Gynecology, Boston University, School of Medicine, Boston, MA, USA. Deborah.Anderson@BMC.org

AIDS (London, England)
|December 17, 2009
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Preparation and Use of HIV-1 Infected Primary CD4+ T-Cells as Target Cells in Natural Killer Cell Cytotoxic Assays
12:07

Preparation and Use of HIV-1 Infected Primary CD4+ T-Cells as Target Cells in Natural Killer Cell Cytotoxic Assays

Published on: March 14, 2011

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

Related Experiment Videos

Last Updated: Jun 17, 2026

Isolation of Leukocytes from Human Breast Milk for Use in an Antibody-dependent Cellular Phagocytosis Assay of HIV Targets
08:12

Isolation of Leukocytes from Human Breast Milk for Use in an Antibody-dependent Cellular Phagocytosis Assay of HIV Targets

Published on: September 6, 2019

Preparation and Use of HIV-1 Infected Primary CD4+ T-Cells as Target Cells in Natural Killer Cell Cytotoxic Assays
12:07

Preparation and Use of HIV-1 Infected Primary CD4+ T-Cells as Target Cells in Natural Killer Cell Cytotoxic Assays

Published on: March 14, 2011

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

Related Concept Videos

Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Articles linked to this work by shared authors, journal, and citation graph.

Assessing efficacy of ADCY10 inhibitors in cervical mucus.

Molecular human reproduction·2026

Biomedical innovations in contraception: gaps, obstacles, and solutions for sexual and reproductive health.

Lancet (London, England)·2025

Sialidases derived from Gardnerella vaginalis and Prevotella timonensis remodel the sperm glycocalyx and impair sperm function.

Glycobiology·2025

Risk factors for misdiagnosis of interstitial ectopic pregnancy.

Emergency radiology·2025

Ectopic pregnancy management and higher risk sexual behavior during the COVID-19 pandemic at a safety net hospital.

Journal of gynecology obstetrics and human reproduction·2025

Sialidases derived from Gardnerella vaginalis and Prevotella timonensis remodel the sperm glycocalyx and impair sperm function.

bioRxiv : the preprint server for biology·2025

Longitudinal trends in copy-years viremia associated with mpox acquisition but not mpox severity in people with HIV.

AIDS (London, England)·2026

Sex differences in long-acting cabotegravir trough concentrations in the SEARCH study in Kenya and Uganda.

AIDS (London, England)·2026

Changes in neurodevelopmental outcomes from 24 to 36 months among children HIV-exposed uninfected (CHEU) and HIV-unexposed (CHU).

AIDS (London, England)·2026

Reframing analytical treatment interruption through participants' and decliners' eyes: insights from an HIV remission trial.

AIDS (London, England)·2026

Ninety-six-week observational outcomes of long-acting injectable HIV therapy in people with adherence challenges, including people who use drugs.

AIDS (London, England)·2026

Evolving drivers of preexposure prophylaxis discontinuation among US MSM, 2018-2024.

AIDS (London, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us